

Francesca Bovis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4226541/publications.pdf>

Version: 2024-02-01

136
papers

3,465
citations

186265

28
h-index

155660

55
g-index

140
all docs

140
docs citations

140
times ranked

4006
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2016, 68, 566-576.	5.6	427
2	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 481-489.	0.9	338
3	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, 3160-3169.	5.6	322
4	Classification criteria for autoinflammatory recurrent fevers. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1025-1032.	0.9	300
5	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 255-263.	5.6	120
6	Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Three-Variable Juvenile Arthritis Disease Activity Score. <i>Arthritis Care and Research</i> , 2014, 66, 1703-1709.	3.4	115
7	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2871-2880.	5.6	101
8	Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. <i>Rheumatology International</i> , 2018, 38, 5-17.	3.0	74
9	Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1357-1362.	0.9	74
10	Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. <i>Arthritis Research and Therapy</i> , 2018, 20, 285.	3.5	71
11	Revised upper limb module for spinal muscular atrophy: 12-month changes. <i>Muscle and Nerve</i> , 2019, 59, 426-430.	2.2	61
12	Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 994-1001.	2.0	59
13	Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 430.	2.7	58
14	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000161.	3.8	57
15	Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 677-686.	3.4	52
16	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. <i>Journal of Pediatrics</i> , 2017, 189, 72-78.e3.	1.8	50
17	Coronary In-Stent Restenosis: Assessment with CT Coronary Angiography. <i>Radiology</i> , 2012, 265, 410-417.	7.3	45
18	A Long-Term Prognostic Value of CT Angiography and Exercise ECG in Patients With Suspected CAD. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 641-650.	5.3	42

#	ARTICLE	IF	CITATIONS
19	Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 57-63.	2.0	41
20	Aortic annulus area assessment by multidetector computed tomography for predicting paravalvular regurgitation in patients undergoing balloon-expandable transcatheter aortic valve implantation. <i>American Heart Journal</i> , 2012, 164, 576-584.	2.7	40
21	Treatment of multiple sclerosis with rituximab: A multicentric Italian "Swiss experience. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1519-1531.	3.0	38
22	Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1263-1272.	3.0	36
23	Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers. <i>Rheumatology</i> , 2020, 59, 344-360.	1.9	36
24	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. <i>Pediatric Rheumatology</i> , 2016, 14, 68.	2.1	35
25	Clinical Variability in Spinal Muscular Atrophy Type III. <i>Annals of Neurology</i> , 2020, 88, 1109-1117.	5.3	34
26	Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103358.	2.0	33
27	Tailoring B cell depletion therapy in MS according to memory B cell monitoring. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	30
28	Role of Alveolar β_2 -Adrenergic Receptors on Lung Fluid Clearance and Exercise Ventilation in Healthy Humans. <i>PLoS ONE</i> , 2013, 8, e61877.	2.5	29
29	Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 505-515.	2.6	27
30	Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1622-1634.	3.7	27
31	Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas. <i>Annals of Neurology</i> , 2018, 84, 621-625.	5.3	26
32	Female Sex and Oligoarthritis Category Are Not Risk Factors for Uveitis in Italian Children with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 1416-1425.	2.0	25
33	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. <i>Arthritis Research and Therapy</i> , 2020, 22, 71.	3.5	25
34	Radiation dose and diagnostic accuracy of multidetector computed tomography for the detection of significant coronary artery stenoses. <i>International Journal of Cardiology</i> , 2012, 160, 155-164.	1.7	24
35	Management of acute ischemic stroke, thrombolysis rate, and predictors of clinical outcome. <i>Neurological Sciences</i> , 2019, 40, 319-326.	1.9	24
36	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101430.	2.0	23

#	ARTICLE	IF	CITATIONS
37	Delineating the Application of Ultrasound in Detecting Synovial Abnormalities of the Subtalar Joint in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1346-1353.	3.4	22
38	Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. <i>Arthritis Care and Research</i> , 2018, 70, 1312-1319.	3.4	19
39	Different trajectories in upper limb and gross motor function in spinal muscular atrophy. <i>Muscle and Nerve</i> , 2021, 64, 552-559.	2.2	18
40	Three-dimensional Shape and Surface Features Distinguish Multiple Sclerosis Lesions from Nonspecific White Matter Disease. <i>Journal of Neuroimaging</i> , 2017, 27, 613-619.	2.0	17
41	Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2501-2508.	2.0	17
42	Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. <i>Neurological Sciences</i> , 2020, 41, 3175-3183.	1.9	16
43	INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 783-791.e4.	3.8	16
44	Occurrence of smooth endoplasmic reticulum aggregates in metaphase II oocytes: relationship with stimulation protocols and outcome of ICSI and IVF cycles. <i>Human Reproduction</i> , 2021, 36, 907-917.	0.9	16
45	Trigeminal and cervical sensitization during the four phases of the migraine cycle in patients with episodic migraine. <i>Headache</i> , 2022, 62, 176-190.	3.9	15
46	A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1064-1073.	3.0	14
47	Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1828-1836.	3.0	14
48	Vascular factors predict polyneuropathy in a non-diabetic elderly population. <i>Neurological Sciences</i> , 2013, 34, 955-962.	1.9	13
49	Outpatient erbium:YAG (2940nm) laser treatment for snoring: a prospective study on 40 patients. <i>Lasers in Medical Science</i> , 2018, 33, 399-406.	2.1	13
50	Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data. <i>BMC Medicine</i> , 2019, 17, 113.	5.5	13
51	Non-invasive mitochondrial DNA quantification on Day 3 predicts blastocyst development: a prospective, blinded, multi-centric study. <i>Molecular Human Reproduction</i> , 2019, 25, 527-537.	2.8	13
52	Oral Antioxidant Treatment of Men Significantly Improves the Reproductive Outcome of IVF Cycles. <i>Journal of Clinical Medicine</i> , 2021, 10, 3254.	2.4	13
53	Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes. <i>Neuromuscular Disorders</i> , 2022, 32, 36-42.	0.6	13
54	Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy. <i>Epidemiology and Infection</i> , 2018, 146, 606-611.	2.1	12

#	ARTICLE	IF	CITATIONS
55	A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1540-1550.	5.6	11
56	Impact of acute-phase complications and interventions on 6-month survival after stroke. A prospective observational study. <i>PLoS ONE</i> , 2018, 13, e0194786.	2.5	11
57	Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 174.	4.8	11
58	Hammersmith Infant Neurological Examination in low-risk infants born very preterm: a longitudinal prospective study. <i>Developmental Medicine and Child Neurology</i> , 2022, 64, 863-870.	2.1	11
59	Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. <i>Rheumatology</i> , 2019, 58, 1196-1205.	1.9	10
60	Disability, burden, and symptoms related to sensitization in migraine patients associate with headache frequency. <i>Scandinavian Journal of Pain</i> , 2021, 21, 766-777.	1.3	10
61	Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	9
62	Cervical musculoskeletal impairments in the 4 phases of the migraine cycle in episodic migraine patients. <i>Cephalalgia</i> , 2022, 42, 827-845.	3.9	9
63	Methods of Implementation of Evidence-Based Stroke Care in Europe. <i>Stroke</i> , 2015, 46, 2252-2259.	2.0	8
64	The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 43-49.	3.0	8
65	The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 35-42.	3.0	8
66	The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 267-274.	3.0	8
67	Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations. <i>Microorganisms</i> , 2020, 8, 2010.	3.6	8
68	Clinical characterization, long-term follow-up, and response to treatment of patients with syndrome of undifferentiated recurrent fever (SURF). <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152024.	3.4	8
69	Retinal Hyperreflecting Foci Associate With Cortical Pathology in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	8
70	The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 75-82.	3.0	7
71	Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study. <i>Microorganisms</i> , 2020, 8, 864.	3.6	7
72	The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 155-161.	3.0	6

#	ARTICLE	IF	CITATIONS
73	Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
74	Prevalence of disability improvement as a potential outcome for multiple sclerosis trials. <i>Multiple Sclerosis Journal</i> , 2021, 27, 706-711.	3.0	6
75	Recurrence and Prognostic Value of Asymptomatic Spinal Cord Lesions in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 463.	2.4	6
76	Trend of estimated glomerular filtration rate during ombitasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. <i>PLoS ONE</i> , 2018, 13, e0192627.	2.5	6
77	The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 403-409.	3.0	5
78	The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 299-306.	3.0	5
79	Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS. <i>Multiple Sclerosis Journal</i> , 2019, 25, 217-223.	3.0	5
80	Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103118.	2.0	5
81	Hyaluronic acid sperm selection significantly improves the clinical outcome of couples with previous ICSI cycles failure. <i>Andrology</i> , 2022, 10, 677-685.	3.5	5
82	Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach. <i>JAMA Neurology</i> , 2022, 79, 821.	9.0	5
83	The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 395-402.	3.0	4
84	The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 27-33.	3.0	4
85	Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2020, 73, 1264-1274.	3.4	4
86	The challenge of early diagnosis of autoimmune lymphoproliferative syndrome in children with suspected autoinflammatory/autoimmune disorders. <i>Rheumatology</i> , 2021, , .	1.9	4
87	The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 67-73.	3.0	3
88	FRI0568...THE USE OF NEXT GENERATION SEQUENCING PANEL IN UNDIFFERENTIATED AUTOINFLAMMATORY DISEASES IDENTIFY A SEPARATE SUBSET OF COLCHICINE-RESPONDER RECURRENT FEVERS DISTINCT FROM PFAPA SYNDROME. , 2019, , .		3
89	Comparison of Placebos and Propensity Score Adjustment in Multiple Sclerosis Nonrandomized Studies. <i>JAMA Neurology</i> , 2020, 77, 902.	9.0	3
90	Pronuclear score improves prediction of embryo implantation success in ICSI cycles. <i>BMC Pregnancy and Childbirth</i> , 2021, 21, 361.	2.4	3

#	ARTICLE	IF	CITATIONS
91	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 251-258.	3.0	2
92	The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 19-26.	3.0	2
93	The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 211-218.	3.0	2
94	The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 139-146.	3.0	2
95	Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection. PLoS ONE, 2020, 15, e0240550.	2.5	2
96	Persistence of Unintegrated HIV DNA Associates With Ongoing NK Cell Activation and CD34+DNAM-1brightCXCR4+ Precursor Turnover in Vertically Infected Patients Despite Successful Antiretroviral Treatment. Frontiers in Immunology, 2022, 13, 847816.	4.8	2
97	The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 235-242.	3.0	1
98	The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 387-393.	3.0	1
99	The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 243-250.	3.0	1
100	The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 83-90.	3.0	1
101	The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 219-226.	3.0	1
102	The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 171-178.	3.0	1
103	Snoring and Sleep-Related Symptoms: A Novel Non-Invasive 808 nm Wavelength Diode Laser Non-Ablative Outpatient Treatment. A Prospective Pilot-Study on 45 Patients. Photonics, 2021, 8, 69.	2.0	1
104	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	3.3	1
105	Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis?. Pediatric Rheumatology, 2014, 12, .	2.1	0
106	Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients. Pediatric Rheumatology, 2014, 12, .	2.1	0
107	The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 59-66.	3.0	0
108	The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 51-58.	3.0	0

#	ARTICLE	IF	CITATIONS
109	The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 227-233.	3.0	0
110	The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 363-369.	3.0	0
111	The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 107-113.	3.0	0
112	The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 283-289.	3.0	0
113	The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 99-105.	3.0	0
114	The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 275-282.	3.0	0
115	The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 347-354.	3.0	0
116	The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 371-377.	3.0	0
117	The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 187-194.	3.0	0
118	The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 115-122.	3.0	0
119	The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 147-153.	3.0	0
120	The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 179-186.	3.0	0
121	The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 291-298.	3.0	0
122	The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 307-313.	3.0	0
123	The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 315-321.	3.0	0
124	The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 331-338.	3.0	0
125	The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 91-98.	3.0	0
126	The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 131-138.	3.0	0

#	ARTICLE	IF	CITATIONS
127	The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 163-169.	3.0	0
128	The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 195-201.	3.0	0
129	The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 203-209.	3.0	0
130	The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 259-265.	3.0	0
131	The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 355-361.	3.0	0
132	The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 379-386.	3.0	0
133	The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 323-329.	3.0	0
134	The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 123-130.	3.0	0
135	The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 339-346.	3.0	0
136	The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 479-488.	0.6	0